natgillin/translations-raw huggingface dataset:
Accordingly a method for manufacturing a laminar construction panel is provided, comprising a first metal plate, a second metal plate, and an acoustic insulation layer, preferably visco-elastic, interposed there between, wherein the first metal plate and the second metal plate are connected to each other by means of a plurality of locally welded joints, that are (more or less regularly) distributed over the laminar construction panel, and which welded joints extend through the area of the acoustic insulation layer. 
HR P20180978 T1 PATENTNI ZAHTJEVI Postupak proizvodnje laminarnog građevnog panela koji se sastoji od prve metalne ploče (1), druge metalne ploče (2) 1 sloja zvučne izolacije (3) smještenog između njih, naznačen time što se prvu metalnu ploču i drugu metalnu ploču spoji jednu s drugom uz pomoć više lokalno zavarenih spojeva, raspodijeljenih po laminarnom građevnom panelu, koji se pružaju kroz površinu sloja zvučne izolacije.
The compound for the use according to claim 1, wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, melanoma, sarcoma, liver cancer, brain tumors, multiple myeloma, and leukemia. 42118961v.1 
Spoj prema zahtjevu 10, gdje rak se odabire iz skupine koju čine rak dojke, rak glave i vrata, rak pluća, rak jajnika, rak gušterače, multipli mijelom, kolorektalni rak, rak prostate, melanom, Kaposijev sarkom, Ewingov sarkom, rak jetre, rak želuca, meduloblastom, tumori mozga i leukemija;
a quinolone carboxylic acid derivative or a pharmaceutically acceptable salt or ester thereof; and 
(a) derivat kinolon karboksilne kiseline ili njegovu farmaceutski prihvatljivu sol ili ester; i
A method according to claim 13 wherein the infection of the plant is caused by a nematode or a fungus. 
Metoda temeljem zahtjeva 56 gdje je zaraza biljke uzrokovana nematodom.
determining and sending corresponding information to the server system controlling the waste collection system; and 
(e) određivanje i slanje odgovarajuće informacije u serverski sustav (100) koji nadzire sustav prikupljanja otpada (10);i
In an embodiment, the first carrier frequency (110) is a licensed frequency assigned to be used by the telecommunications network (10). 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je prva noseća frekvencija (110) licencirana frekvencija određena za korištenje u telekomunikacijskoj mreži (10).
The liposome formulation of claim 18, wherein the divalent cation is Ca2+. 
Liposomska formulacija u skladu s patentnim zahtjevom 18, naznačena time što je dvovalentni kation Ca".
The method of claim 1, wherein the recombinant adenosine deaminase is according to SEQ ID NO: 1 or SEQ ID NO: 5, with an amino acid substitution selected from the group consisting of Gln in place of Lys198; Ala in place of Thr245; Arg in place of Gly351 and combinations thereof. 
Adenozin-deaminaza, namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 15-17, naznačena time što je rekombinantna adenozin-deaminaza u skladu s SEQ ID NO: 1 ili SEQ ID NO: 5, gdje se aminokiselinska supstitucija bira iz skupine koju čine Gln umjesto Lysiog; Ala umjesto Thr4s; Arg umjesto Glyss1, te njihove kombinacije.
The method according to any one of the preceding embodiments, wherein the number of oil droplets having a size of > 1.2 µm after filtration is 5 x 108 /ml or less. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um nakon filtracije je 5 x 105 /ml ili manje.
wherein the heteroaryl and heterocyclyl groups are unsubstituted or substituted by one or more substituents selected from a halogen atom, a hydroxyl group, a cyano group, a linear or branched C1-C4 alkyl group or a C1-C4 haloalkyl group, 
pri čemu su heteroarilna i heterociklička grupa nesupstituirane ili supstituirane s jednim ili više supstituenata odabranih iz atoma halogena, hidroksilne grupe, cijano grupe, linearne ili razgranate C1-C4 alkilne grupe ili C1-C4 haloalkilne grupe,
A compound of formula (4), or salt thereof, 
Spoj sa formulom (4), ili njegova sol,:
correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the sample, 
(d) koreliranju prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku; i
wherein represents C1 to 2 alkyl, cyclopropyl, OCH3, SCH3 or OCF3; said alkyl or cyclopropyl group being optionally further substituted by one or more fluoro atoms; and 
R' predstavlja Cl do 2 alkil, ciklopropil, OCH,, SCH. ili OCF,; a navedena alkilna ili ciklopropilna skupina eventualno može biti dodatno supstituirana sa jednim ili više fluoro atoma; i R" predstavlja C1 do 3 alkil.
In all the subsequent examples, the dissolution of the prepared tablets was determined in a paddle apparatus. 
U svim primjerima koji slijede, otapanje pripremljenih tableta određeno je u paddle uređaju.
The SIP Proxy Server of claim 1, further designed to: 
SIP proksi server sukladno zahtjevu 1, nadalje dizajniran da:
when aligned with any of SEQ ID NOs: 20 to 38, 58 to 76 and 77 to 95 using a pairwise alignment algorithm, each moving window of x amino acids from N terminus to C terminus has at least x·y identical aligned amino acids, where x is 30 and y is 0.75, wherein the immunogenic polypeptide raises a substantially similar immune response in a subject as the E. coli AcfD (orf3526) protein. 
20 do 38, 58 do 76 1 77 do 95 koristeći algoritam za parno svrstavanje, svaki pokretni dio x amino kiselina od N terminala do C terminala ima barem x.y jednako poredanih amino kiselina, gdje x je 30 i y je 0.75, pri čemu imunogenski polipeptid podiže značajno sličan imuni odaziv u subjektu kao E. coli AcfD (orf3526) protein.
The composition of claim 7, comprising 35-45% (w/w) carbohydrates obtainable from carob, 35-45% (w/w) carbohydrates obtainable from apple, 5-15 % (w/w) carbohydrates obtainable from grape, and 5-15% (w/w) carbohydrates obtainable from pear, wherein the percentages are based on the dry matter. 
Pripravak u skladu s patentnim zahtjevom 6, naznačen time što sadrži 35-45% (tež./tež.) ugljikohidrata koji se mogu dobiti iz rogača, 35-45% (tež./tež.) ugljikohidrata koje se mogu dobiti iz jabuke, 5-15 % (tež./tež.) ugljikohidrata koji se mogu dobiti iz grožđa, te 5-15% (tež./tež.) ugljikohidrata koji se mogu dobiti iz kruške, gdje se postoci baziraju na suhoj tvari.
In one embodiment the disclosure provides a neutralising antibody having specificity for human IL-17A and human IL-17F, comprising a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO: 1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3. 
Neutralizirajuće protutijelo prema zahtjevu 1, naznačeno time da se veže za humani IL-17A i humani i IL-17F koji sadrži teški lanac, pri čemu varijabilno područje jakog lanca sadrži sekvencu danu u SEQ ID NO:1 za CDR- H1, sekvencu danu u SEQ ID NO:2 za CDR-H2 i sekvencu danu u SEQ ID NO:3 za CDR-H3.
In further embodiments the recombinant Sendai viral vectors described herein wherein at least a gene start/stop site is manipulated to alter gene transcription. 
Rekombinantni virus Sendai kao vektor u skladu s patentnim zahtjevima 1,2,3,4 ili 5, naznačen time što je u najmanju ruku mjesto početka/prestanka gena tako izmanipulirano da promijeni transkripciju gena.
The method of any of claims 1 - 5 wherein the first set of components comprises alumina particles with an average particle size greater than 1 mm. 
Metoda iz bilo kojeg od patentnih zahtjeva 1-5 pri čemu prvi set komponenata obuhvaća čestice aluminija prosječne veličine čestica veće od 1 mm.
During spraying of a mixture containing a biologically active or chemical substance from bottle 20A, valve 94 would be in a position to block channel 92B to container 20B. 
Tijekom raspršivanja mješavine koja sadrži neku biološki aktivnu ili kemijsku supstancu iz boce 20A, ventil 94 blokira cjevovod 92B do boce 20B.
The compound according to claim 1, or a stereoisomer or pharmaceutically-acceptable salt thereof, having the formula: 
Å BE iš ili stereoizomer, tautomer, farmaceutski-prihvatljivu sol, ili solvat tog spoja.
In some forms of embodiment, the vegetable extracts are contained in the first region of the chewing gum. 
Žvakaća guma prema jednom ili više od patentnih zahtjeva 1-3, naznačeno time da su rečeni biljni ekstrakti sadržani u rečenoj prvoj regiji.
As shown in FIG. 1, the lid is composed of two components, but it is contemplated that a one-piece or multi-piece cap may also be used. 
Kako je prikazano na Slici 1, poklopac se sastoji od dva dijela, ali smatra se kako se također može koristiti poklopac u jednom dijelu ili višedijelni.
The method according to claim 1, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer. 
Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je rak odabran iz skupine koja se sastoji od raka dojke, raka prostate, raka kostiju, kolorektalnog raka, leukemije, limfoma, raka kože, raka jednjaka, raka želuca, astrocitnog raka, raka endometrijuma, raka vrata materice, raka mokraćnog mjehura, raka bubrega, raka pluća, raka jetre, raka štitnjače, raka glave i vrata, raka gušterače i raka jajnika.
An isolated IL-23p19 antibody, wherein said antibody binds to human IL-23p19 or a fragment thereof at an epitope specific to one or more portions of SEQ ID NO: 1 comprising amino acid residues 93-102, 93-110, and/or 127-137 of SEQ ID NO: 1. 
Izolirano IL-23p19 protutijelo, naznačeno time što se navedeno protutijelo veže za IL-23p19 ili za njegov ulomak na epitopu koji sadrži ostatke aminokiselina 93-102 SEQ ID NO: 1.
Use of (a) a B2 agonist as defined in any one of claims 1 and 3 to 7, for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 19 or 12. 
Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
Method and system for transmitting satellite signals and receiver thereof 
METODA I SISTEM ZA PRIJENOS SATELITSKIH SIGNALA I PRIJEMNIK ISTIH
A method for inhibiting VR1 function in a cell, comprising in vitro contacting a cell capable of expressing VR1 with an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof. 
Postupak za inhibiranje VR1 funkcije u stanici, naznačen time, da se sastoji od in vitro dovođenja u dodir stanice, sposobne da eksprimira VRI, s učinkovitom količinom spoja iz patentnog zahtjeva 1 ili njegove farmacoutski prihvatljive soli.
Coupling is carried out with a mixture of amino acid, HOBT and DICI which is stirred 30 minutes at RT, and then added to the resin at once. 
Kupiranje je provedeno u smjesi amino kiselina, HOBT i DICI koji su miješani tijekom 30 minuta na RT te se nakon toga dodala smola odjednom.
The method of claim 11, wherein the testing device comprises one or more test scripts, including test commands defined therein which, when executed by the media device under test, cause the media device under test to issue requests for the playback or other control of media content associated with the test files. 
Postupak prema zahtjevu 6 ili 7, naznačen time da sustav sadrži jednu ili više testnih skripti (340), uključujući definirane testne naredbe koje, kada se izvršavaju putem medijskog uređaja (350) prilikom testiranja, uzrokuju da medijski uređaj izdaje zahtjeve za pristup mediju za nadziranje, npr. za reprodukciju, medijskog sadržaja povezanog s testnim datotekama (332, 334, 336).
is selected from the series consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl, phenyl, Het2 and Het3, wherein (C1-C6)-alkyl, (C3-C7)-cycloalkyl and Het2 all are unsubstituted or substituted by one or more identical or different substituents R10, and phenyl and Het3 all are unsubstituted or substituted by one or more identical or different substituents R13; 
R7 se bira iz skupine koju čine (C;-C4)-alkil, (C3-C7)-cikloalkil, fenil, Het2 i Het3, pri čemu (C;,-Cs)-alkil, (C3-C7)- cikloalkil i Het2 su svi nesupstituirani ili je supstituiran s jednim ili više istih ili različitih supstituenata R10, i fenil i Het3 su svi nesupstituirani ili je supstituiran s jednim ili više istih ili različitih supstituenata R13;
7 a and 7 b show schematically a dispensing valve 30 for the dispensing assembly according to the invention. 
Slike 7a i 7b prikazuju shematski ventil za točenje 30 koji se koristi u sklopu za točenje prema izumu.
A process for the synthesis of the compound according to claim 10, comprising a step of salification of pemetrexed (5) by protonated lysine in accordance with claim 1. 
Postupak sinteze spoja u skladu s patentnim zahtjevom 10, naznačen time, da sadržava korak salifikacije pemetrekseda (5) protoniranim lizinom u skladu s patentnim zahtjevom 1.
and R7 or R8 and R9 together with the carbon atoms to which they are attached form an optionally substituted carbocyclic ring, or a heterocyclyl optionally substituted by C1-C6alkyl or C1-C6haloalkyl; wherein a "carbocyclic ring" means a cycloalkyl or cycloalkenyl group; and wherein, when present, the optional substituents on cycloalkyl or cycloalkenyl are C1-C3alkyl; or 
i R7 ili R8 i R9 zajedno s atomima ugljika na koje su oni spojeni tvore proizvoljno supstituirani karbociklički prsten, ili heterociklil proizvoljno supstituiran s C1-C6alkilom ili C1-C6haloalkilom; pri čemu "karbociklički prsten" predstavlja cikloalkil ili cikloalkenil skupinu; te pri čemu, kada su prisutni, proizvoljni supstituenti na cikloalkilu ili cikloalkenilu su C1-C3alkil; ili
The method of claim 3 or 4, wherein the addition of a pH modifying solution comprises spray addition of the pH modifying solution. 
Postupak prema zahtjevu 3 ili 4, naznačen time, da dodavanje pH-modificirane otopine obuhvaća dodatno raspršivanje pH-modificirane otopine.
is hydrogen. 
Ru je vodik.
The mixture was stirred at 50° C. for 16 hours. THF was removed in vacuo, the aq. solution was washed with ether, and cooled at 0° C. Neutralization with 5% aq. citric acid (6.0 mL, 4.7 mmol)) gave a precipitate, which was collected and further purified by column chromatography on silica gel with MeOH/DCM/triethylamine 8/100/2 to afford compound 7-1 (0.56 g, 84%) as a white solid. 
Smjesu se miješa 16 sati na 50 *C. THF se ukloni u vakuumu, vodenu otopinu ispere eterom, te ohladi na 0 "C. Neutraliziranjem 5 %-tnom vodenom otopinom limunske kiseline (6,0 ml, 4,7. mmol)) dobije se talog, kojeg se prikupi, te daljnje pročisti kromatografijom na stupcu silikagela, uz eluiranje smjesom MeOH/DCMftrietilamin 8:100:2 kako bi se dobilo spoj 7-1 (0,56 g, 84 %) u obliku bijele krutine.
The molecule of claim 3, wherein binding of the molecule to said protein, aggregation of said protein or downregulation of the biological function of said protein in a subject is therapeutically useful in inflammatory disease, such as wherein the expression or overexpression of said protein is associated with or causative of inflammatory disease, for use in treatment of inflammatory disease. A molecule of the following structure: (X2i-1-Yi-X2i-Zi)n, wherein: 
Molekula u skladu s patentnim zahtjevom 3, naznačena time, da je vezanje molekule na navedeni protein, agregacija navedenog proteina ili smanjenje regulacije biološke funkcije navedenog proteina kod subjekta terapeutski korisno u upalnim bolestima, kao primjerice kada je ekspresija ili prekomjerna ekspresija navedenog proteina povezana s ili uzrokuje upalnu bolest, za upotrebu u liječenju upalne bolesti.
Figures 7a and 7b show schematically a dispensing valve 30 for the dispensing assembly. 
Slike 7a i 7b prikazuju shematski ventil za točenje 30 koji se koristi u sklopu za točenje prema izumu.
A void space 62 formed by end 58 also helps to inhibit migration of the aerosol former to the fuel. 
Prazan proslor 62 formiran pomoću kraja 58 također pomaže da se inhibira migracija aerosola (njegovog formirača) prema gorivu.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
The crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione of claim 14, wherein the X-ray powder diffraction peaks are at 7.9, 14.4 and 15.8 degrees 2θ. 
Kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion u skladu s patentnim zahtjevom 14, naznačen time što pikovi difrakcije rendgenskih zraka na prahu su na 7,9, 14,4 i 15,8 stupnjeva 2θ.
In the case of the SU-MIMO transmission, where the two CWs (CW#0 and CW#1) are transmitted in a plurality of layers, resource amount determining section 204 determines the amount of resource for each of the plurality of layers, the amount of the resource being allocated to control information (ACK/NACK signals) allocated in the two CWs (CW#0 and CW#1). 
Terminalni uređaj (200) koji prenosi kontrolnu informaciju u pluralitetu slojeva, uređaj sadržeći: sekciju određivanja (204) koja određuje količinu resursa kontrolne informacije u pluralitetu slojeva; i sekciju prijenosa (206) koja prenosi kontrolnu informaciju na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa Qcwso+cwsr kontrolne informacije određena jednadžbom 1: čiči iii u GEAR *
A first outer dimension of the packaging may be between 135.1 and 136.8 millimeters. 
Prva vanjska dimenzija pakiranja može biti između 135.1 i 136.8 milimetara.
The composition for use of claim 17 or the use of claim 18, wherein the disorder is an ocular disease such as age-related macular degeneration or diabetic retinopathy. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 16, ili upotreba u skladu s patentnim zahtjevom 17, naznačen time što je poremećaj: očna bolest, poput staračke degeneracije makule ili dijabetične retinopatije; ili
mixing 4-15% by weight of an alkoxy-silane compound, 20-85% by weight of a methacrylic-silane monomer with 1-4% of an organic solvent at an acidic pH, 
miješanje 4-15 tež.% alkoksi-silanovog spoja, 20-85 tež.% trimetoksipropilsilan metakrilata s 1-4 tež.% organskog otapala kod kiselog pH,
CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2. The method according to claim 9, wherein said antigen-presenting cell comprises an expression vector expressing said peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2,pri čemu opcionalno stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
The method of claim 1, wherein said reaction chamber is located in or adjacent to the pay zone of the oil reservoir. 
Postupak prema patentnom zahtjevul8, naznačen time, da je navedena reakcijska komora smještena u zoni iskoristivosti naftnog ležišta ili neposredno uz nju.
The roulette wheel apparatus according to claim 1, wherein the ball launcher comprises two rotatable elements defining a gap between them and arranged to accelerate a roulette ball passing through the gap. 
Uređaj s kolom za rulet u skladu s patentnim zahtjevom 1, naznačen time što lanser kuglice sadrži dva zakretljiva elementa koji omeđuju procjep između sebe i služe za ubrzavanje kuglice za rulet koja prolazi kroz procjep.
and in that the control unit (11) is adapted to control the valve member (93, 93b, 95, 97) as well as the valve device (13) according to at least one further of the following settings: 
priključak otvoren i desni i lijevi otvor ispušnog kraka potpuno zatvoreni; i pri čemu je kontrolna jedinica (11) prilagođena da kontrolira element ventila (9) kao i uređaj ventila (13) u skladu s najmanje jednom od sljedećih dodatnih postavki:
in part (b), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:111 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 110; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 111 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 110;
An internet service provider according to claim 12 or 13, wherein the private routing protocol is one of dynamic and static. 
Davatelj internetskih usluga u skladu s patentnim zahtjevom 12 ili 13, naznačen time što je privatni protokol za usmjeravanje jedan dinamički 1 statički.
A method of producing a humanized antibody comprising culturing the host cell of claim 9 under conditions supporting expression of a humanized antibody that binds to VLQELNVTV (SEQ ID NO: 45) when bound by an HLA-A2 receptor. 
Postupak za proizvodnju humaniziranog antitijela koji obuhvaća uzgoj u kulturi stanice domaćina prema zahtjevu 9 pod uvjetima koji podržavaju ekspresiju humaniziranog antitijela koje vezuje VLQELNVTV (SEQ ID NO: 45) kada se veže za HLA-A2 receptor.
angling down the second panel with respect to the first panel, until both panels are situated in the same plane, 
zakretanje prema dole drugog panela (1, 42, 43, 46, 53, 57) u odnosu na prvi panel (1, 42, 43, 46, 53, 57), sve dok oba panela ne budu smještena u istu ravninu,
A composition comprising the monoclonal antibody or functional part thereof according to claim 1 or 2 in a therapeutically effective amount, wherein the composition optionally further comprises a pharmaceutically acceptable carrier. 
Sastav koja sadrži antitijelo ili njegov funkcionalni dio prema bilo kojem od zahtjeva 1-4, naznačen time što opcijski dalje sadrži farmaceutski prihvatljiv nosač.
The pharmaceutical composition of claim 15, wherein said one or more additional therapeutic agents are selected from agents that target a B cell antigen other than CD37, preferably said B cell antigen is CD20. 
Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeni jedno ili više terapeutskih sredstava su sredstva koja ciljaju na antigen CD20 od B-stanice.
Amides of the formula X can be prepared by acidic rearrangement (e.g. treatment in a solution of trifluoroacetic acid) of amides of formula IV analogous to methods described in the literature (Hamel, P.; Girard, M.; Tsou, N. N.; J. Heterocyclic Chem. 
Amidi formule X mogu se pripremati kiselim premještanjem (npr. tretiranjem u otopini trifluoroacetne kiseline) amida formule IV analogno metodama opisanim u literaturi (Hamel, P.; Girard, M; Tsou, N.N.; J. Heterocyclic Chem.
Preparations and Examples 
Priprava i primjeri izvođenja